The risk for MACE was similar with IL-17A inhibitors, IL-23 inhibitors, and IL-12/23 inhibitors vs TNF inhibitors among patients with psoriasis or psoriatic arthritis. Though patients with psoriasis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback